Measuring the Beat: 57 Stocks Surpassing Earnings Expectations
Academic research has consistently found that corporate earnings surprises cluster around small positive values, rather than large outperformance.
Amneal Pharmaceuticals Inc. (AMRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 10,168,660 | $176,019,505 | -8% | 1.61% |
| 2. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,268,751 | $39,272,080 | -21% | 1.31% |
| 3. | Blackbarn Capital Jonathan Carter | 1,300,000 | $22,503,000 | -22% | 1.9% |
| 4. | Citadel Investment Group Ken Griffin | 1,118,715 | $19,364,957 | +94% | 0% |
| 5. | AQR Capital Management Cliff Asness | 795,028 | $13,761,935 | -9% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.21 | 50,000 | $210,500.00 | 258,784 | 2021-12-17 | Filing | |
| $4.25 | 50,000 | $212,500.00 | 512,566 | 2021-12-16 | Filing | |
| $4.13 | 100,000 | $413,000.00 | 462,566 | 2021-12-15 | Filing | |
| $4.25 | 50,000 | $212,500.00 | 512,566 | 2021-12-16 | Filing | |
| $4.13 | 100,000 | $413,000.00 | 462,566 | 2021-12-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.64 | 50,000 | $882,000.00 | 210,252 | 2026-08-13 | Filing | |
| $17.51 | 146,403 | $2,563,516.53 | 253,390 | 2026-08-12 | Filing | |
| $17.40 | 210,000 | $3,654,000.00 | 35,171 | 2026-08-12 | Filing | |
| $17.70 | 6,613 | $117,050.10 | 245,171 | 2026-08-11 | Filing | |
| $12.94 | 34,819 | $450,557.86 | 93,660 | 2026-05-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 26,562,093 | $459,789,829 | 0.01% | |
| 2. | 12,328,767 | $213,410,957 | 4.27% | |
| 3. | 12,137,727 | $210,104,054 | 0.01% | |
| 4. | 7,710,126 | $133,462,281 | 0% | |
| 5. | 7,356,977 | $127,349,272 | 0% |
News See All
9 Best Drug Stocks to Buy According to Analysts
On April 27, Jurrien Timmer, director of global macro at Fidelity Investments, appeared on CNBC to talk about the market and oil prices, and how necessary it is for oil prices to retreat from their highs...
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2025 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2025 Earnings Call Transcript February 27, 2026Amneal Pharmaceuticals, Inc. misses on earnings expectations.
Amneal Pharmaceuticals, Inc. (AMRX) Added to S&P SmallCap 600 Index, Boosting Investor Visibility
Separately, on January 29, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced that it would be added to the S&P SmallCap 600 Index. It is a popular benchmark for U.S.
7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds
According to research, the U.S.
Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best performing pharma stocks in 2025. On January 7, Truist raised the price target on Amneal Pharmaceuticals, Inc.
10 Best Performing Pharma Stocks in 2025
On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook...
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is among the 13 Most Undervalued Stocks Under $20 to Buy.
13 Most Undervalued Stocks Under $20 to Buy
The Nasdaq Composite slumped 3% last week, while the S&P 500 index was down 1.8% with leading AI stocks losing over $820 billion in market capitalization, as concerns over overvaluation sparked a substantial...
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q3 2025 Earnings Call Transcript
Anthony DiMeo: Good morning, and thank you for joining Amneal Pharmaceuticals' third quarter 2025 earnings call. Today we issued a press release reporting Q3 results.
Hedge Fund Resource Center